Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies

Recent studies have shown a suboptimal humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients diagnosed with hematologic malignancies; however, data about cellular immunogenicity are scarce. The aim of this study was to evaluate bot...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez, Moraima, Roldán, Elisa, Fernández-Naval, Candela, Villacampa, Guillermo, Martinez-Gallo, Mónica, Medina-Gil, Daniel, Peralta-Garzón, Soraya, Pujadas, Gemma, Hernández, Cristina, Pagès, Carlota, Gironella, Mercedes, Fox, Laura, Orti, Guillermo, Barba, Pere, Pumarola, Tomás, Cabirta, Alba, Catalá, Eva, Valentín, Mercedes, Marín-Niebla, Ana, Orfao, Alberto, González, Marcos, Campins, Magda, Ruiz-Camps, Isabel, Valcárcel, David, Bosch, Francesc, Hernández, Manuel, Crespo, Marta, Esperalba, Juliana, Abrisqueta, Pau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632354/
https://www.ncbi.nlm.nih.gov/pubmed/34844263
http://dx.doi.org/10.1182/bloodadvances.2021006101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632354/
https://www.ncbi.nlm.nih.gov/pubmed/34844263
http://dx.doi.org/10.1182/bloodadvances.2021006101

Ejemplares similares